Jordyn Sava is an editor for Targeted Oncology.
Real-World Findings on TLS Prevention and Management With Venetoclax in CLL
July 8th 2024Mark Geyer, MD, and Yannis K. Valtis, MD, delved into the background and findings from a study looking at clinical and laboratory tumor lysis syndrome in patients with CLL who were treated with venetoclax in the inpatient and outpatient settings.
FDA Issues CRL to Patritumab Deruxtecan in Advanced EGFR-Mutated NSCLC
June 27th 2024Patritumab deruxtecan has been issued a complete response letter to its biologics license application for the treatment for patients with advanced non-small cell lung cancer with EGFR mutations after prior treatment with 2 or more lines of therapy.
Liposomal Irinotecan Shows Comparable Efficacy With Topotecan in Relapsed SCLC
June 18th 2024While the primary end point of overall survival was not met in the phase 3 RESILIENT study, the overall response rate was 44.1% vs 21.6% with liposomal irinotecan vs topotecan in relapsed small cell lung cancer.
Durvalumab Plus Chemotherapy Wins FDA Approval in dMMR Endometrial Cancer
June 14th 2024The FDA has approved a treatment regimen combining durvalumab with carboplatin and paclitaxel, followed by durvalumab monotherapy, for adults with primary advanced or recurrent endometrial cancer that is deficient in mismatch repair.